Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

COMy Virtual 2020 | Immunotherapy in myeloma – where are we?

Keith Stewart • 30 Apr 2020
COMy Virtual 2020
Multiple Myeloma Antibodies CAR-T Idecabtagene vicleucel

Keith Stewart, MB, ChB, Mayo Clinic, Rochester, MN, discusses the role of immunotherapy in multiple myeloma (MM), particularly T-cell engaging therapies. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Keith Stewart

The future of myeloma therapy
The future of myeloma therapy
Keith Stewart • 15 Apr 2023
Day 2 wrap-up: pushing myeloma boundaries
10:38
Day 2 wrap-up: pushing myeloma boundaries
Keith Stewart • 27 Mar 2022
Day 1 highlights: peripheral blood MRD, AB amyloid treatment, single-cell & metabolomics
11:10
Day 1 highlights: peripheral blood MRD, AB amyloid treatment, single-cell & metabolomics
Keith Stewart • 26 Mar 2022
Drug resistance in multiple myeloma
5:02
Drug resistance in multiple myeloma
Keith Stewart • 30 Apr 2020

Related Videos

A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
3:11
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
Keith Stewart • 7 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Keith Stewart • 15 Dec 2025
Motixafortide + G-CSF HSC mobilization in pts with myeloma following quadruplet induction therapy
1:40
Motixafortide + G-CSF HSC mobilization in pts with myeloma following quadruplet induction therapy
Keith Stewart • 6 Dec 2025
WGS of cfDNA for assessment of MRD in high-risk smoldering multiple myeloma
2:13
WGS of cfDNA for assessment of MRD in high-risk smoldering multiple myeloma
Keith Stewart • 8 Dec 2025
The content of VJHemOnc is intended for healthcare professionals